Introduction
============

Central nervous system (CNS) atypical teratoid/rhabdoid tumors (ATRTs) are highly malignant. ATRT accounts for 1%-2% of CNS tumors in children of all ages, but 10%-20% in patients younger than 3 years \[[@b1-crt-2015-347],[@b2-crt-2015-347]\]. ATRTs are distinguished from other embryonal brain tumors not only by the presence of rhabdoid cells and specific immunohistochemistry but also by biological markers \[[@b3-crt-2015-347]\]. CNS ATRTs are associated with significantly worse overall survival (OS) than other embryonal tumors \[[@b4-crt-2015-347]-[@b6-crt-2015-347]\]. The very poor prognosis of ATRT in young children may be related to the limited use of radiotherapy (RT) because of the risks of functional impairment of the developing brain and late adverse effects \[[@b7-crt-2015-347]\]. Multiple chemotherapeutic approaches have been attempted to defer radiation; however, OS remains dismal. For older children, a few studies have suggested that outcome might be improved with standard-dose craniospinal RT (CSRT) and high-dose alkylator-based chemotherapy \[[@b2-crt-2015-347]\]. However, various late adverse effects primarily attributable to RT, particularly CSRT, were unavoidable.

A treatment strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) has shown clinical benefit in children with high-risk or recurrent solid tumors including brain tumors \[[@b8-crt-2015-347]-[@b12-crt-2015-347]\], and recent studies have suggested that further dose intensification using tandem HDCT/auto-SCT might improve outcomes and/or reduce RT dose without jeopardizing survival rates \[[@b13-crt-2015-347]-[@b15-crt-2015-347]\]. Gajjar et al. \[[@b13-crt-2015-347]\] reported the results of a prospective study (SJMB 96 study) employing tandem HDCT/auto-SCT in patients with high-risk medulloblastoma. In their study, patients received 36.0-39.6 Gy of CSRT followed by four cycles of HDCT/auto-SCT, and the 5-year event-free survival (EFS) rate was 70% \[[@b13-crt-2015-347]\]. Previous reports from our institution also suggested that tandem HDCT/auto-SCT with deferred and/or reduced RT was feasible and might further improve outcomes in young children with brain tumors and patients (\> 3 years of age) with high-risk medulloblastoma \[[@b13-crt-2015-347],[@b14-crt-2015-347]\]. In the current study, we prospectively evaluated the effectiveness of tandem HDCT/auto-SCT in children with ATRT. The aim of our new treatment strategy was to improve patient survival while reducing the risks of late adverse effects from RT.

Materials and Methods
=====================

This study is a pilot study including a small cohort of patients with ATRT in a single institution. The study was approved by the Institutional Review Board of Samsung Medical Center (2004-12-009 and 2011-06-081), Seoul, Korea, and conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. All parents and guardians gave their written informed consent before enrollment.

1. Patients
-----------

Children diagnosed with ATRT from November 2004 to June 2012 were enrolled in the study. All cases and loss of nuclear expression of INI1 was confirmed by immunohistochemical staining by a pediatric neuropathologist. Disease extent at diagnosis was assessed using brain and spinal magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) cytology.

2. Induction chemotherapy
-------------------------

The treatment scheme is shown in [Fig. 1](#f1-crt-2015-347){ref-type="fig"}. Induction treatment was initiated within 4 weeks, and preferably within 3 weeks, after surgery. For young children, six cycles of induction chemotherapy were administered prior to HDCT/auto-SCT, and consisted of alternating CECV (cisplatin+etoposide +cyclophosphamide+vincristine) and CEIV (carboplatin+ etoposide+ifosfamide+vincristine) regimens ([Table 1](#t1-crt-2015-347){ref-type="table"}). RT was deferred until after 3 years of age unless the tumor showed relapse or progression. For older children, a total of six cycles of induction chemotherapy were administered prior to tandem HDCT/auto-SCT. During the early study period (diagnosis between November 2004 and December 2011), two cycles of pre-RT and four cycles of post-RT chemotherapy (75% of calculated dose) were administered. During the late study period (diagnosis from January 2012), when RT was administered after surgery without preceding chemotherapy, six cycles of post-RT chemotherapy were administered. Post-RT chemotherapy was initiated within 4 weeks after completion of RT, and the doses were reduced by 25% of the calculated dose because of the long-lasting myelosuppressive effect of CSRT. Induction chemotherapy cycles were scheduled 28 days apart. If needed, delays were permitted to allow recovery of the absolute neutrophil count (ANC) and platelet count to 1,000 and 100,000/mm^3^, respectively. Peripheral blood stem cells (PBSCs) were collected during the recovery phase of the first chemotherapy cycle in the early study period, or after surgery (steady state mobilization with granulocyte-colony stimulating factor for 4-5 days) in the late study period.

3. Radiotherapy
---------------

For young children, RT was either not given or was deferred until after 3 years of age if the patient achieved complete response (CR) after tandem HDCT/auto-SCT. Use of RT was determined according to the tumor status at the time of diagnosis. Local RT (L-RT) by 3-dimensional conformal RT (30.6 Gy, 1.8 Gy/fraction) was administered after 3 years of age only if gross residual tumor (\> 1.5 cm2) remained after initial or second-look surgery. For L-RT to the primary site, the radiation target volume was defined as the postoperative surgical cavity and residual tumor (if present) with 1-2 cm margins. CSRT (23.4 Gy, 1.8 Gy/fraction) was administered after 3 years of age only if leptomeningeal seeding was present at the time of diagnosis. However, both CSRT and boost L-RT were administered immediately if the patient had not achieved CR after tandem HDCT/auto-SCT ([Fig. 1](#f1-crt-2015-347){ref-type="fig"}).

For older children with primary tumor at cerebrum, during the early study period, RT consisted of 23.4 Gy (30.6 Gy if M+) of CSRT, 30.6 Gy (23.4 Gy if M+) of boost L-RT to the primary site, and 14.4 Gy of boost RT to the gross seeding nodule (if present). During the early study period, two patients experienced progression before initiation of RT. Therefore, in the late study period, RT was administered after surgery without preceding chemotherapy.

4. Tandem HDCT/auto-SCT
-----------------------

The regimens for the first and second HDCT/auto-SCT were CTE (carboplatin+thiotepa+etoposide) and CM (cyclophosphamide+melphalan), respectively ([Table 1](#t1-crt-2015-347){ref-type="table"}). An approximately 12-week interval without treatment was allowed between the first and second HDCT/auto-SCT. Approximately half of the PBSCs collected during a single round of leukapheresis were infused for marrow rescue during each HDCT/auto-SCT session.

5. Response and toxicity criteria
---------------------------------

Disease response was evaluated by brain and spinal MRI and CSF cytology every two cycles of chemotherapy, after RT, between the first and second HDCT/auto-SCT, every 3 months for the first year after completion of HDCT/auto-SCT, every 4 months for the second year, and every 6 months thereafter. Tumor size was estimated by MRI as the product of the greatest diameter and the longest perpendicular diameter. Disease responses were categorized as follows: progressive disease, greater than a 25% increase in tumor size or the appearance of a new area of tumor; stable disease, less than a 25% change in tumor size; minor response, 25% to 50% decrease in tumor size; partial response, greater than a 50% decrease in tumor size; CR, complete disappearance of all previously measurable tumor; or continuous CR, continuous CR. Toxicities were graded using the Common Terminology Criteria ver. 4.0 of the National Cancer Institute.

6. Evaluation of late adverse effects
-------------------------------------

Late adverse effects were evaluated annually after completion of HDCT/auto-SCT. The diagnosis of growth hormone deficiency was based on a declining growth rate and was confirmed by biochemical testing. Hypothyroidism was diagnosed by elevation of thyrotropin. Adrenal insufficiency was diagnosed based on the failure to increase cortisol levels after administration of corticotropin releasing hormone. Cognitive function was evaluated using the Korean-Wechsler Intelligence Scale for Children-IV or Korean-Wechsler Adult Intelligence Scale-IV. Cardiac, renal, hepatic, auditory, and ophthalmologic functions were also evaluated.

7. Statistics
-------------

This study is a pilot study including a small cohort of patients with ATRT. The primary aim of the study is to improve patient survival while reducing the risks of late adverse effects from RT. EFS was calculated from the date of diagnosis until the date of relapse, progression, or death, whichever occurred first. OS was calculated from the date of diagnosis until death from any cause. Survival rates and standard errors were estimated using the Kaplan-Meier method, and differences in survival rates between the two groups were compared using the log-rank test. Differences in the frequencies of clinical characteristics between the two age groups were analyzed using a chi-square test or Fisher exact test. p-values less than 0.05 were considered significant.

Results
=======

1. Patient characteristics
--------------------------

Thirteen consecutive patients (three boys and 10 girls) with ATRT were enrolled during the study period. Patient characteristics are listed in [Table 2](#t2-crt-2015-347){ref-type="table"}. The median age at diagnosis was 79 months (range, 2 to 181 months), and five patients were younger than 3 years at diagnosis. Gross total resection or near total resection (\> 90% resection) was possible in five patients and subtotal resection (50%-90% resection) or less was performed in the eight remaining patients. Eight patients had metastatic disease (M1 in one, M2 in one, and M3 in six according to the Chang staging system \[[@b16-crt-2015-347]\]). Four patients had tumors at the posterior fossa, eight at the supratentorial area, and one at the spinal cord. Although four of five young patients had tumors at the posterior fossa, all of the older patients had tumors at sites other than the posterior fossa (p=0.010). All of the young patients had leptomeningeal seeding at diagnosis, compared with only three of eight older patients (p=0.024).

2. Induction chemotherapy
-------------------------

The grade 3/4 toxicity profile during a total of 62 cycles of induction chemotherapy is shown in [Table 2](#t2-crt-2015-347){ref-type="table"}. Hematologic toxicity was generally acceptable. The median duration of neutropenia (ANC \< 500/mm^3^) was 7.5 days (range, 1 to 20 days) and the median interval between chemotherapy cycles was 29 days (range, 24 to 58 days). Delay in scheduled chemotherapy of more than 7 days occurred in only eight cycles (12.9%) (four from delayed hematologic recovery, two from shunt problems, and two from HDCT scheduling), and chemotherapy dose reduction of more than 5% occurred in only three cycles (4.8%). Neutropenic fever which was experienced by all patients occurred in 36 cycles (58.1%) and four episodes (6.5%) of blood stream infection were documented. Non-hematologic toxicity was not common during induction chemotherapy ([Table 2](#t2-crt-2015-347){ref-type="table"}). The response to induction treatment is shown in [Table 3](#t3-crt-2015-347){ref-type="table"}. Tumor relapse or progression during induction chemotherapy occurred in three of five young patients, two of whom died of tumor progression. Three of eight older patients experienced progression (two before RT and one after RT). Among these six cases of progression or relapse during induction treatment, four patients (one young and three older) received salvage treatment including RT and chemotherapy, and three (one young and two older) proceeded to HDCT/auto-SCT. During the three leukapheresis procedures performed per patient, the median number of CD34^+^ cells collected was 41.7×10^6^/kg (range, 3.1×10^6^/kg to 119.5×10^6^/kg).

3. Radiotherapy
---------------

The RT doses administered to 10 patients are shown in [Table 3](#t3-crt-2015-347){ref-type="table"}. Two of five young patients received 23.4 Gy of CSRT and 30.6 Gy of boost L-RT at 41 and 22 months of age, respectively, because they did not achieve CR after tandem HDCT/auto-SCT. The three remaining young patients did not receive RT due to death after progression or failure to obtain parental consent. Five older patients without leptomeningeal seeding also received 23.4 Gy of CSRT and 30.6 Gy of boost L-RT. One older M+ patient received 30.6 Gy of CSRT and 23.4 Gy of boost L-RT, and one patient (No. 11) received rescue RT (36.0 Gy of CSRT and 18.0 Gy of boost L-RT) after progression. The remaining patient (No. 12) with spinal ATRT received 36.0 Gy of CSRT, 18 Gy of boost L-RT to the primary site, and 14.4 Gy of boost RT to the seeding nodule. In summary, eight patients received RT as scheduled without deviation.

4. Tandem HDCT/auto-SCT
-----------------------

Seven patients could proceed to HDCT/auto-SCT without progression during induction treatment. Another three patients underwent HDCT/auto-SCT as salvage treatment after relapse/progression during induction treatment. Eight of 10 patients who underwent the first HDCT/auto-SCT proceeded to the second HDCT/auto-SCT. The two remaining patients could not proceed to the second HDCT/auto-SCT because of tumor progression (patient No. 2) and refusal by parent (patients No. 13), respectively. The median doses of HDCTs were 99.2% and 99.1% of the calculated dose based on body surface area in the first and second HDCT/auto-SCTs, respectively. In one patient (patient No. 5) who was younger than 1 year at the time of HDCT/auto-SCT, the dose was calculated based on body weight. The median interval from day 0 of the first HDCT/auto-SCT to initiation of the second HDCT/auto-SCT was 84 days (range, 75 to 93 days). The grade 3/4 toxicity profile of patients receiving tandem HDCT/auto-SCT is shown in [Table 4](#t4-crt-2015-347){ref-type="table"}. Both the neutrophil and platelet counts recovered rapidly during the first and second HDCT/auto-SCT. During the first HDCT/auto-SCT, frequent grade 3/4 toxicities included fever, stomatitis, elevation of liver enzymes, and hypokalemia. Toxicities were milder during the second HDCT/auto-SCT compared with the first. No treatment-related mortality (TRM) occurred during the tandem HDCT/auto-SCT.

5. Survival
-----------

Tumor relapse or progression during induction treatment occurred in six (three young and three older) patients, all of whom died from tumor progression. All three patients who underwent HDCT/auto-SCT as salvage treatment after relapse/progression experienced progression again and died at 2, 2, and 25 months post-transplant. Among seven (two young and five older) patients who could proceed to HDCT/auto-SCT without relapse or progression, three (two young and one older) patients experienced relapse or progression after tandem HDCT/auto-SCT. The remaining four older patients remain progression free. Among eight patients who were in less than CR before tandem HDCT/auto-SCT, three patients achieved CR after tandem HDCT/auto-SCT and two patients remain event free. Two of five M0 older patients who received 23.4 Gy of CSRT experienced progression; however, the sites of progression were the primary sites. Although all five young patients experienced relapse/progression and died from disease progression, four of eight older patients remain progression free. Overall, nine patients experienced relapse/progression at a median follow-up period of 5 months (range, 1 to 73 months) from diagnosis and four patients remain event free at a median follow-up period of 64 months (range, 39 to 108 months) from diagnosis. For all patients, the 5-year EFS and OS rates were 38.5±13.5% and 34.6±14.4%, respectively ([Fig. 2](#f2-crt-2015-347){ref-type="fig"}). For young patients, the 5-year EFS and OS rates were both zero. However, for older patients, the 5-year EFS and OS rates were 62.5±17.1% and 62.5±17.1%, respectively.

6. Late adverse effects
-----------------------

Five patients who remained event free for more than 1 year after HDCT/auto-SCT were evaluated for various late adverse effects. Late effects observed at a median of 35 months (range, 12 to 59 months) after the second HDCT/auto-SCT were hypothyroidism (n=1), growth hormone deficiency (n=1), sex hormone deficiency (n=2), and sensory neural hearing loss (n=2). However, all late effects were grade 1/2 toxicities. In two patients who received treatment during the prepubertal period, a deceleration in vertical growth was prominent and growth hormone replacement was initiated in one patient. The median value for full-scale IQ evaluated at a median of 21 months (range, 20 to 66 months) after RT was 80 (range, 55 to 103).

Discussion
==========

The efficacy of many different treatments has been explored with the aim of improving the survival of ATRT patients; however, there is no consensus regarding standard chemotherapy. In the current study, CECV and CEIV regimens were used for induction treatment. Although toxicities were not significant with the exception of neutropenic fever, many patients experienced progression during induction chemotherapy. Gardner et al. \[[@b11-crt-2015-347]\] reported a possible benefit in patients who received methotrexate. In the study by Chi et al. \[[@b20-crt-2015-347]\] using the Intergroup Rhabdomyosarcoma III (IRS-III)-based regimen, the combination of intrathecal chemotherapy with focal radiation was an effective strategy for disease control in young patients. These findings suggest that incorporation of methotrexate, use of an IRS-III--based regimen, and inthrathecal chemotherapy might improve the outcome.

A few retrospective analyses and prospective studies have suggested that patients who received HDCT/auto-SCT have a higher survival rate than those who did not ([Table 5](#t5-crt-2015-347){ref-type="table"}). However, because of the small patient numbers, various chemotherapy regimens, and additional salvage treatment that often included RT, no real conclusions can be made from published data regarding the role of HDCT/auto-SCT in ATRT. In the current study we used tandem HDCT/auto-SCT to further increase the intensity of chemotherapy. However, the number of patients enrolled was too small and patients were treated with several different modalities, therefore, it is still difficult to determine the role of tandem HDCT/auto-SCT. Our study has the same limitations of previous studies, as described above.

The optimal combination of regimens for tandem HDCT has not yet been determined. Variable intensity of tandem HDCT regimens and the length of the interval between the first and second HDCT/auto-SCT cycles may affect outcome and toxicity profile. The intensities of our HDCT regimens are stronger or similar to those reported in previous studies for ATRT ([Table 5](#t5-crt-2015-347){ref-type="table"}). In our previous study, we showed that adequate rest is required between the first and second HDCT/auto-SCT cycles when using very intensive HDCT regimens \[[@b21-crt-2015-347]\]. In the current study, very intensive HDCT regimens were used in both the first and second HDCT/auto-SCT cycles; therefore, a 12-week interval was implemented to reduce toxicities during the second HDCT/auto-SCT. As a result, toxicities were manageable and there was no TRM during HDCT/auto-SCT in both young and older children. However, further dose-escalation during tandem HDCT/auto-SCT might be associated with more significant late adverse effects than single HDCT/auto-SCT. Therefore, longer follow-up and randomized trials including a larger cohort of patients are needed to determine whether the possible survival benefits of tandem HDCT/auto-SCT over single HDCT/auto-SCT ultimately outweigh the adverse effects associated with dose-intense tandem HDCT/auto-SCT.

Unacceptable adverse effects of RT for young children with brain tumors led a number of institutions and national groups to adopt chemotherapy-based strategies designed to avoid or delay RT \[[@b22-crt-2015-347],[@b23-crt-2015-347]\]. In the current study, we evaluated the effectiveness of tandem HDCT/auto-SCT in young children with ATRT with the aim of both improving survival and avoiding or deferring RT until after the most radiosensitive neurodevelopmental mileposts. However, the outcome was very disappointing, mainly as a result of early progression. In our experience, intensive systemic chemotherapy alone was not an effective method to avoid or defer RT in young patients with ATRT, suggesting that RT should be considered much earlier in therapy. Some clinical trials now incorporate focal radiation at a much younger age than previously considered appropriate \[[@b17-crt-2015-347],[@b24-crt-2015-347],[@b25-crt-2015-347]\]. Intrathecal chemotherapy may also have potential benefit as an additional means to avoid RT or to intensify therapy in patients who are not candidates for CSRT \[[@b5-crt-2015-347],[@b20-crt-2015-347]\]. Taken together, these data suggest that early administration of RT to the primary site together with intrathecal chemotherapy might prevent early progression and eventually improve the outcome, as reported in the study by Chi et al. \[[@b20-crt-2015-347]\].

In our recent study of patients older than 3 years with high-risk medulloblastoma, we were able to reduce the CSRT dose by employing tandem HDCT/auto-SCT without jeopardizing survival rates \[[@b15-crt-2015-347]\]. The dose of CSRT was reduced to 23.4 Gy (M0) or 30.6 Gy (M+) with the goal of reducing late adverse effects from CSRT. In that study, the probability of 5-year EFS was 70.0±10.3% for all patients and 70.6±11.1% for patients with metastasis. The same strategy was applied in the current study for ATRT patients older than 3 years. Three of five M0 patients who received 23.4 Gy of CSRT remained progression free and the site of progression in the two remaining patients was the primary tumor site, not metastatic sites. Findings of the current study suggest that 23.4 Gy of CSRT might be sufficient to prevent metastatic relapse in M0 patients older than 3 years if the intensity of chemotherapy is increased. However, further study is necessary.

While four of seven patients who could proceed to HDCT/auto-SCT without relapse or progression remain progression free after HDCT/auto-SCT, all three patients who underwent HDCT/auto-SCT as salvage treatment after relapse/progression experienced progression again. These findings suggest that pre-HDCT tumor status is important for prediction of outcome and careful consideration is required for selection of candidate patients for HDCT/auto-SCT.

Conclusion
==========

Intensive systemic chemotherapy including HDCT/auto-SCT alone as a method to avoid RT is not effective in young children with disseminated ATRT. Therefore, early RT combined with or without intrathecal chemotherapy as a substitute for CSRT should be considered for young children. For older children without leptomeningeal seeding, our results suggest that dose-intense chemotherapy may decrease the required dose of CSRT without jeopardizing survival. However, further cooperative studies with a larger cohort of patients are needed to evaluate the effectiveness of our strategy.
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![Treatment scheme. For young children, six cycles of induction chemotherapy were administered prior to HDCT/auto-SCT, consisting of alternating CECV and CEIV regimens. RT was either not administered or was deferred until after 3 years of age if the patient achieved complete response after tandem HDCT/auto-SCT. Use of RT was determined according to the tumor status at the time of diagnosis. For older children, two cycles of pre-RT and four cycles of post-RT chemotherapy were administered during the early study period. During the late study period when RT was administered after surgery, six cycles of post-RT chemotherapy were administered. The regimens for the first and second HDCT/auto-SCT were CTE and CM, respectively. HDCT/auto-SCT, high-dose chemotherapy and autologous stem cell transplantation; CECV, carboplatin+etoposide+ cyclophosphamide+vincristine; CEIV, carboplatin+etoposide+ifosfamide+vincristine; RT, radiotherapy; CSRT, craniospinal RT; L-RT, local RT; Dx, diagnosis; CTE, carboplatin+thiotepa+etoposide; CM, cyclophosphamide+melphalan.](crt-2015-347f1){#f1-crt-2015-347}

![Although all five young patients experienced relapse/progression and died from disease progression, four of the eight older patients remained event free at a median follow-up period of 64 months (range, 39 to 108 months) from diagnosis. For all patients, the 5-year event-free survival (EFS) and overall survival (OS) rates were 38.5±13.5% and 34.6±14.4%, respectively.](crt-2015-347f2){#f2-crt-2015-347}

###### 

Chemotherapy regimens

  Regimen                                                Drug               Dose (mg/m^2^/day)   Schedule              Total dose (mg/m^2^)
  ------------------------------------------------------ ------------------ -------------------- --------------------- ----------------------
  **Induction regimen**                                                                                                
   CECV^[a)](#tfn1-crt-2015-347){ref-type="table-fn"}^   Cisplatin          90                   Day 0                 90
                                                         Etoposide          75                   Days 0-2              225
                                                         Cyclophosphamide   1,500                Days 1 and 2          3,000
                                                         Vincristine        1.5                  Days 0 and 7          3.0
                                                                                                                       
   CEIV^[a)](#tfn1-crt-2015-347){ref-type="table-fn"}^   Carboplatin        300                  Days 0 and 1          600
                                                         Etoposide          75                   Days 0-4              375
                                                         Ifosfamide         1,500                Days 0-4              7,500
                                                         Vincristine        1.5                  Days 0 and 7          3.0
  **HDCT regimen**                                                                                                     
   First: CTE                                            Carboplatin        500                  Days -8, -7, -6       1,500
                                                         Thiotepa           300                  Days -5, -4, -3       900
                                                         Etoposide          250                  Days -5, -4, -3       750
   Second: CM                                            Cyclophosphamide   1,500                Days -8, -7, -6, -5   6,000
                                                         Melphalan          60                   Days -4, -3, -2       180

CECV, carboplatin+etoposide+cyclophosphamide+vincristine; CEIV, carboplatin+etoposide+ifosfamide+vincristine; HDCT, high-dose chemotherapy; CTE, carboplatin+thiotepa+etoposide; CM, cyclophosphamide+melphalan.

Dose was determined based on body weight in children under 3 years of age.

###### 

Grade 3/4 toxicity profile of induction chemotherapy

  Parameter                                                               Pre-RT chemotherapy                                       Post-RT chemotherapy   Total (62 cycles)                                                             
  ----------------------------------------------------------------------- --------------------------------------------------------- ---------------------- ------------------- --------------------------------------------------------- ------------
  **Hematologic toxicity**                                                                                                                                                                                                               
   Chemotherapy dose (%)^[a)](#tfn2-crt-2015-347){ref-type="table-fn"}^   99.6 (79.5-104.5)                                         100 (79.1-102.8)       74.5 (70.4-76.7)    73.6 (69.5-76.5)                                          \-
   Dose reduction \> 5%                                                   1 (5.6)                                                   1 (5.9)                0                   1 (7.7)                                                   3 (4.8)
   Interval to next cycle (day)                                           29 (24-58)                                                32 (25-37)             28 (26-39)          32 (27-38)                                                29 (24-58)
   Interval \> 35 days                                                    2 (11.1)                                                  1 (5.9)                1 (7.1)             4 (30.8)                                                  8 (12.9)
   Delayed hematologic recovery                                           0                                                         1 (5.9)                1 (7.1)             2 (15.4)                                                  4 (6.5)
   Other causes                                                           2 (11.1)^[b)](#tfn3-crt-2015-347){ref-type="table-fn"}^   0                      0                   2 (15.4)^[c)](#tfn4-crt-2015-347){ref-type="table-fn"}^   4 (6.5)
   Duration of neutropenia (day)                                          8 (4-11)                                                  8 (4-20)               8 (5-15)            6 (1-12)                                                  7.5 (1-20)
   No. of platelet transfusions                                           4 (1-10)                                                  3 (0-14)               2 (1-8)             3 (1-8)                                                   3 (0-14)
   Neutropenic fever                                                      12 (66.7)                                                 8 (47.1)               9 (64.3)            7 (53.8)                                                  36 (58.1)
   Positive blood culture                                                 1 (5.6)                                                   2 (11.8)               0                   1 (7.7)                                                   4 (6.5)
  **Non-hematologic toxicity**                                                                                                                                                                                                           
   Elevation of liver enzymes                                             1 (5.6)                                                   1 (5.9)                0                   0                                                         2 (3.2)
   Hyperbilirubinemia                                                     0                                                         0                      0                   0                                                         0
   Renal insufficiency                                                    0                                                         0                      0                   0                                                         0
   Hypokalemia                                                            2 (11.1)                                                  2 (11.8)               0                   1 (7.7)                                                   5 (8.1)
   Hyponatremia                                                           1 (5.6)                                                   0                      0                   0                                                         1 (1.6)

Values are presented as median (range) or number (%). CECV, cisplatin+etoposide+cyclophosphamide+vincristine; CEIV, carboplatin+etoposide+ifosfamide+vincristine.

Percent of calculated dose,

Delay due to shunt problems,

Delay due to high-dose chemotherapy scheduling.

###### 

Patient characteristics, treatment, and outcome

  No.   Sex      Age at Dx (mo)   Primary site   Results of surgery                                  M stage^[a)](#tfn5-crt-2015-347){ref-type="table-fn"}^   Treatment after surgery and response                                                             Tumor status before HDCT1                            Tumor status after HDCT1   Tumor status after HDCT2   Outcome                        Site of failure
  ----- -------- ---------------- -------------- --------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------------------------------------------------- -------------------------- -------------------------- ------------------------------ -----------------
  1     Female   20               PF             GTR                                                 1                                                        AB--PD                                                                                           \-                                                   \-                         \-                         3 mo dead, PD at 2 mo          P+M
  5     Female   3                PF             NTR                                                 3                                                        ABABAB--HDCT1--HDCT2--PD                                                                         PR                                                   PR                         PR                         15 mo dead, PD at 14 mo        M
  8     Female   29               T              STR                                                 3                                                        ABABAB--HDCT1--HDCT2--RT (23.4-30.6-0)^[b)](#tfn6-crt-2015-347){ref-type="table-fn"}^--Relapse   PR                                                   CR                         CCR                        23 mo dead, relapse at 22 mo   P+M
  9     Female   9                PF             STR                                                 3                                                        ABABAB--PD--Surgery (STR)--HDCT1--HDCT2--RT (23.4-30.6-0)--PD                                    PR2^[c)](#tfn7-crt-2015-347){ref-type="table-fn"}^   PR                         PR                         37 mo dead, PD at 7 mo         P+M
  10    Female   2                PF             STR                                                 2                                                        ABA--PD                                                                                          \-                                                                              \-                         6 mo dead, PD at 5 mo          P+M
  2     Female   177              T              NTR                                                 0                                                        AB--RT (23.4-30.6-0)--PD--Surgery (GTR)--A--PD--RT (0-30.0-0)--HDCT1--PD                         PD                                                   PD                         \-                         12 mo dead, PD at 6 mo         P
  3     Female   180              F              GTR                                                 0                                                        AB--RT (23.4-30.6-0)--ABAB--HDCT1--HDCT2                                                         CCR                                                  CCR                        CCR                        108+ mo alive, Ds free         \-
  4     Male     181              P-O            STR                                                 0                                                        AB--PD--RT (23.4-30.6-0)--Surgery (NTR)--PD                                                      \-                                                   \-                         \-                         9 mo dead, PD at 2 mo          P
  6     Female   154              F              GTR                                                 0                                                        AB--RT (23.4-30.6-0)--ABAB--HDCT1--HDCT2                                                         CCR                                                  CCR                        CCR                        85+ mo alive, Ds free          \-
  7     Male     79               T              STR                                                 3                                                        AB--RT (30.6-23.4-0)--ABAB--HDCT1--HDCT2                                                         PR                                                   CR                         CCR                        73 mo dead, relapse at 73 mo   P
  11    Female   43               LV             STR                                                 3                                                        PD after surgery--AB--RT (36.0-18.0-0)--PD--A--HDCT1--PD--HDCT2--PD                              PD                                                   PD                         PD                         14 mo dead, PD at 1 mo         M
  12    Female   93               SC             STR                                                 3                                                        RT (36.0-18.0-14.4)--ABABAB--HDCT1--HDCT2                                                        PR                                                   PR                         CR                         43+ mo alive, Ds free          \-
  13    Male     171              TV             Bx^[d)](#tfn8-crt-2015-347){ref-type="table-fn"}^   0                                                        RT (23.4-30.6-0)--ABABAB--HDCT1--Surgery (GTR)^[e)](#tfn9-crt-2015-347){ref-type="table-fn"}^    PR                                                   PR                         \-                         39+ mo alive, Ds free          \-

Dx, diagnosis; HDCT1, first high-dose chemotherapy; HDCT2, second high-dose chemotherapy; PF, posterior fossa; GTR, gross total resection; A, CECV (carboplatin+etoposide+cyclophosphamide+vincristine) regimen; B, CEIV (carboplatin+etoposide+ifosfamide+vincristine) regimen; PD, progression; P, primary site; M, metastatic site; NTR, near total resection; PR, partial response; T, temporal lobe; STR, subtotal resection; RT, radiotherapy; CR, complete response; CCR, continuous CR; PR2, second PR; F, frontal lobe; Ds, disease; P-O, parieto-occipital lobe; LV, lateral ventricle; SC, spinal cord; TV, third ventricle; Bx, biopsy; CSF, cerebrospinal fluid.

M stage; 0, no leptomeningeal seeding; 1, positive CSF cytology; 2, seeding at cerebrum; 3, seeding at spinal cord,

RT dose (Gy) to craniospinal-primary (boost)- gross seeding nodule (boost),

PR2 was achieved by second-look surgery, not by chemotherapy or RT,

Only biopsy was possible due to severe tumor bleeding during surgery and cognitive function worsened after surgery,

No viable tumor cells were found.

###### 

Grade 3/4 toxicity profile of tandem HDCT/auto-SCT

  Parameter                                                                               First HDCT/auto-SCT (n=10)   Second HDCT/auto-SCT (n=8)   p-value
  --------------------------------------------------------------------------------------- ---------------------------- ---------------------------- ----------
  **Hematologic toxicity**                                                                                                                          
   CD34^+^ cells (×10^6^/kg)                                                              10.3 (1.7-47.5)              14.0 (1.3-40.2)              0.633
   Days^[a)](#tfn10-crt-2015-347){ref-type="table-fn"}^ to reach ANC 500/mm^3^            9 (8-11)                     9.5 (8-11)                   0.360
   Days^[b)](#tfn11-crt-2015-347){ref-type="table-fn"}^ to reach PLT count 20,000/mm^3^   18 (16-52)                   20 (16-64)                   0.963
   Days of BT ≥ 38.0°C                                                                    4.5 (1-6)                    3 (0-5)                      0.360
   Positive blood culture (No. of patients)                                               4                            1                            0.314
  **Non-hematologic toxicity (No. of patients)**                                                                                                    
   Stomatitis                                                                             7                            1                            0.025
   Vomiting                                                                               1                            0                            0.556
   Diarrhea                                                                               3                            0                            0.216
   Elevation of liver enzymes                                                             7                            0                            0.004
   Hyperbilirubinemia                                                                     1                            0                            0.556
   Renal insufficiency                                                                    0                            0                            \> 0.999
   Hypokalemia                                                                            5                            1                            0.036
   Hyperkalemia                                                                           0                            0                            \> 0.999
   Hyponatremia                                                                           2                            1                            0.588
   Hypernatremia                                                                          0                            0                            \> 0.999
   Hepatic VOD                                                                            1                            1                            0.706
   Myocarditis                                                                            0                            0                            \> 0.999
   Seizure                                                                                2                            0                            0.477
   Treatment-related mortality                                                            0                            0                            \> 0.999

Values are presented as median (range) or number. HDCT/auto-SCT, high-dose chemotherapy and autologous stem cell transplantation; ANC, absolute neutrophil count; PLT, platelet; BT, body temperature; VOD, veno-occlusive disease.

The first of 3 consecutive days that ANC exceeded 500/mm^3^,

The first of 7 consecutive days that PLT count exceeded 20,000/mm^3^ without transfusion.

###### 

Summary of previous clinical series using HDCT/auto-SCT for children with ATRT

  Source                                                       Type of study          No of patients                                                                                            Age, median (range, mo)^[a)](#tfn12-crt-2015-347){ref-type="table-fn"}^   Pre-HDCT chemotherapy^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^   HDCT regimenb)                                              RT^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^                                                                                          Final survival outcome
  ------------------------------------------------------------ ---------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Hilden et al. (2004) \[[@b1-crt-2015-347]\]                  Retrospective review   42^[a)](#tfn12-crt-2015-347){ref-type="table-fn"}^ (13)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^   24 (1-118)                                                                Multiple regimens                                                       CT×3 (5), others (8)                                        None (8), L-RT (3), CSI (1), CSI+L-RT (1)                                                                                                   NED (6), DOD (6), TD (1)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^
  Tekautz et al. (2005) \[[@b2-crt-2015-347]\]                 SJMB96                 9 (7)                                                                                                     All \> 36                                                                 \-                                                                      CpCyV4                                                      CSI+L-RT before HDCT (7)                                                                                                                    NED (5), AWD (1), DOD (1)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^
  Gardner et al. (2008) \[[@b11-crt-2015-347]\]                Head Start-I           6 (2)                                                                                                     35.5 (4-45)                                                               0, 3 cycles                                                             CTE (2)                                                     None (2)                                                                                                                                    DOD (2)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^, 3-yr EFS 0%^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^
  Head Start-II                                                7 (5)                  28 (5-52)                                                                                                 5 cycles                                                                  CTE (5)                                                                 None (3), CSI+L-RT after HDCT (1), L-RT after relapse (1)   NED (3), DOD (1), TD (1)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^, 3-yr EFS 43±19%^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^   
  Finkelstein-Shechter et al. (2010) \[[@b17-crt-2015-347]\]   Retrospective review   8 (6)                                                                                                     35 (11-43)                                                                3 cycles (5), IRS-III (1)                                               CT×3                                                        None (4), L-RT before HDCT (1), L-RT after HDCT (1)                                                                                         NED (4), DOD (2)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^
  Lafay-Cousin et al. (2012) \[[@b6-crt-2015-347]\]            Retrospective review   50 (18)                                                                                                   17 (1-188)                                                                Multiple regimens                                                       CTE (4), CT3 (14)                                           NA                                                                                                                                          Alive (9), median survival 40.8 mo^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^; 2-yr OS 48±12%^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^
  Park et al. (2012) \[[@b18-crt-2015-347]\]                   KSPNO S-082            9 (6)                                                                                                     12 (4-28)                                                                 6 cycles (5), 4 cycles (1)                                              First: CTE, Second: CM                                      None (1), L-RT before HDCT (1), CSI+L-RT after HDCT (4)                                                                                     NED (4), AWD (1), DOD (1)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^; 3-yr EFS 0%, 3-yr OS 53±17%^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^
  Zaky et al. (2014) \[[@b19-crt-2015-347]\]                   Head Start-III         19 (5)                                                                                                    13 (7-27)                                                                 5 cycles                                                                CTE                                                         None (4), CSI+L-RT after relapse (1)                                                                                                        NED (3), AWD (1), DOD (1)^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^; 3-yr EFS 21±9%, 3-yr OS 26±10%^[b)](#tfn13-crt-2015-347){ref-type="table-fn"}^

HDCT/autoSCT, high-dose chemotherapy and autologous stem cell transplantation; ATRT, atypical teratoid/rhabdoid tumor; RT, radiotherapy; CT, carboplatin+thiotepa; L-RT, local RT; CSI, craniospinal irradiation; NED, no evidence of disease; DOD, died of disease; TD, toxic death; CpCyV, cisplatin+cyclophosphamide vincristine; AWD, alive with disease; IRS-III, Intergroup Rhabdomyosarcoma III; CTE, carboplatin+thiotepa+etoposide; EFS, event-free survival; NA, not available; OS, overall survival; CM, cyclophosphamide+melphalan.

Data of all patients,

Data of patients who underwent HDCT.

[^1]: Ki Woong Sung and Do Hoon Lim contributed equally to this work.
